Innovative Bispecific Nanobody Targeting CD3 Complex and CLDN18 for Next-Generation Cancer Immunotherapy
VHH-P520 is a cutting-edge, fully humanized nanobody-based therapeutic candidate specifically designed to target both the CD3 Complex (T Cell Receptor Complex) and claudin 18 (CLDN18), two crucial molecules implicated in tumor immunotherapy. Currently in the Biological Testing stage, VHH-P520 leverages advanced bispecific antibody engineering to precisely engage immune effector cells and tumor cells, offering a novel mechanism with significant therapeutic potential for the treatment of cancer. The dual-targeting approach underpins its promise in overcoming resistance and driving meaningful anti-tumor responses across diverse indications in oncology.
| Candidate | VHH-P520 |
| Target | CD3 Complex (T Cell Receptor Complex) claudin 18 (CLDN18) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P520 is currently available for out-licensing and partnering opportunities. We welcome inquiries from pharmaceutical and biotech enterprises seeking strategic collaboration in advancing the next generation of cancer immunotherapies.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P520 |
Modality
VHH-P520 utilizes a bispecific IgG4 kappa antibody format, comprising an antibody-binding fragment and variable domain targeting claudin 18.2, as well as a Fab engaging CD3, expressed in Chinese hamster ovary cells. The innovative nanobody structure, characterized by its small molecular size and high stability, ensures superior tissue penetration and robust target engagement. These properties are particularly advantageous in the oncological context, where dense tumor architecture and heterogeneous antigen distribution pose challenges for conventional antibody therapeutics. The modular architecture further enables enhanced manufacturability and scalability of the product for broad clinical application in cancer therapy.
Target
CD3 Complex and CLDN18 are pivotal targets in modern cancer immunotherapy. CD3 Complex is a critical component of T-cell biology, mediating immune activation when engaged. By targeting CD3 Complex, therapeutic agents can redirect T-cell activity toward malignant cells. CLDN18, on the other hand, is a tight junction protein with restricted expression to certain normal tissues but is aberrantly overexpressed in various cancers, facilitating tumor growth and survival. The concurrent targeting of CD3 Complex and CLDN18 enables precise immune synapse formation at the tumor site while minimizing off-tumor effects. This dual engagement approach maximizes the immunotherapeutic index, offering an attractive strategy for difficult-to-treat malignancies and supporting the strategic positioning of VHH-P520 in the immuno-oncology landscape.
Mechanism of Action
VHH-P520 exerts its anti-cancer activity by simultaneously binding to CD3 Complex on effector T cells and CLDN18 on tumor cells, triggering immune cell recruitment and activation at the tumor site. The bispecific architecture enables bridging of T cells to malignant cells, leading to targeted cytotoxicity and tumor cell elimination. Through its nanobody-based platform, VHH-P520 offers potential for further development as antibody-drug conjugates (ADCs) or other multi-specific immunotherapies, expanding therapeutic possibilities. By modulating key signal transduction events, VHH-P520 initiates immune synapse formation and activation cascades that are critical for potent anti-tumor responses, representing a highly differentiated mechanism for cancer therapy.
Cancer
Cancer remains a leading cause of morbidity and mortality worldwide, with millions of new cases and deaths each year. Despite significant advances, current cancer therapies—including chemotherapy, radiation, and targeted therapies—are often limited by non-specific toxicity, acquired resistance, and heterogeneous response rates. Immunotherapies have reshaped the treatment landscape, yet many tumors remain refractory or develop adaptive resistance. There is a pronounced need for novel agents capable of overcoming these clinical hurdles. VHH-P520, by concurrently targeting CD3 Complex and CLDN18, proposes a transformative approach to engage and direct the immune system with precision. This dual-targeting nanobody therapeutic is poised to address significant unmet needs for more effective, selective, and durable cancer treatments, offering new hope for patients with refractory or relapsed disease.